89 Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo

Zr immuno-PET continues to be assessed in numerous clinical trials. This report evaluates the use of Zr-chloride in the radiolabeling of monoclonal antibodies conjugated with desferrioxamine B (DFO), describes its effects on radiopharmaceutical reactivity toward antigen, and offers guidance on how t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Nuclear Medicine 2019-05, Vol.60 (5), p.696-701
Hauptverfasser: Pandya, Darpan N, Bhatt, Nikunj B, Almaguel, Frankis, Rideout-Danner, Stephanie, Gage, Howard D, Solingapuram Sai, Kiran Kumar, Wadas, Thaddeus J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Zr immuno-PET continues to be assessed in numerous clinical trials. This report evaluates the use of Zr-chloride in the radiolabeling of monoclonal antibodies conjugated with desferrioxamine B (DFO), describes its effects on radiopharmaceutical reactivity toward antigen, and offers guidance on how to ensure long-term stability and purity. Zr-DFO-trastuzumab and Zr-DFO-cetuximab were prepared using ZrCl The stability of each was evaluated for 7 d in 20 mM histidine/240 mM sucrose buffer, 0.25 M sodium acetate (NaOAc) buffer containing 5 mg·mL -acetyl-l-cysteine (NAC), or 0.25 M NaOAc containing 5 mg·mL l-methionine (L-MET). To assess antigen reactivity, Zr-DFO-trastuzumab was evaluated using the Lindmo method and tested in PET/CT imaging of mouse models of human epidermal growth factor receptor 2-positive or -negative lung cancer. Using ZrCl , Zr-DFO-trastuzumab and Zr-DFO-cetuximab were prepared with increased specific activity and retained purities of 95% after 3 d when formulated in NaOAc buffer containing L-MET. Based on Lindmo analysis and small-animal PET/CT imaging, Zr-DFO-trastuzumab remained reactive toward antigen after being prepared with ZrCl ZrCl facilitated the radiosynthesis of Zr immuno-PET agents with increased specific activity. L-MET enhanced long-term solution stability better than all other formulations examined, and Zr-DFO-trastuzumab remained reactive toward antigen. Although further evaluation is necessary, these initial results suggest that ZrCl may be useful in immuno-PET radiochemistry as radiolabeled monoclonal antibodies are increasingly integrated into precision medicine strategies.
ISSN:0161-5505
1535-5667
2159-662X
DOI:10.2967/jnumed.118.216457